AstraZeneca (AZN LN) Obesity pill helps patients lose 10.5% of body weight in trial after 26 weeks vs 0.6% with placebo
- Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio
- Aadults with obesity or overweight and at least one comorbidity receiving elecoglipron (75mg) achieved a clinically meaningful and statistically significant average reduction in body weight of 10.5% at 26 weeks compared to 0.6% with placebo, a dual primary endpoint.
- Weight loss in participants receiving elecoglipron did not plateau, reaching 11.8% at 36 weeks (75mg) versus 0.3% with placebo.
- The trial also met the dual primary endpoint of proportion of participants achieving at least 5% weight loss at 26 weeks, with up to 88.8% of participants receiving elecoglipron achieving this threshold.
#UNITED KINGDOM#EUROPE#ELI LILLY & CO#LLY.US#ASTRAZENECA PLC#AZN.LN#3I GROUP PLC#IMPORTANT#EQUITIES#US SESSION#PHARMACEUTICALS#ASSET MANAGEMENT & CUSTODY BANKS#PHARMACEUTICALS (GROUP)#CAPITAL MARKETS#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#FINANCIAL SERVICES#S&P 500 INDEX#FTSE 100 INDEX#ELI LILLY AND CO#LLY#III#GLOBAL EQUITIES